Medical facility BHealthcare enters partnership with three European diagnostic labs for the procurement of over thirty autonomous blood-drawing devices.
BHealthCare's Autonomous Blood Drawing Device HEIVA Expands Presence in Europe
BHealthCare, a European MedTech company specializing in autonomous robotic solutions for peripheral vascular access, has made significant strides in its flagship product, HEIVA. The autonomous blood drawing device, which was developed in 2020 and has since undergone pilot clinical evaluation, has secured supply agreements with three European medical biology laboratories for pre-orders.
The news was reported by Digital Health & AI Insights, although it does not provide new information about BHealthCare or HEIVA beyond this announcement. The number of pre-orders for HEIVA exceeds 30 from a growing list of medical labs.
HEIVA is set to be the first robotic technology to autonomously draw blood samples from among hundreds of thousands of daily patients using the services at selected major European medical laboratory groups. The company is currently conducting a fundraising round with the aim of completing HEIVA's pivotal clinical trial and launching its industrial manufacturing process.
BHealthCare anticipates obtaining CE marking for HEIVA next year, and the device is currently in the registration process to obtain GCC approval. Since its founding in late 2016, BHealthCare has raised 13.5 million EUR (15M USD) in capital funds and grants, making it one of the first MedTech companies in Europe, and among only a handful in the world, capable of offering this robotic autonomous blood drawing technology.
As for market expansion beyond Europe and the Middle East, opportunities would likely include North America, Asia-Pacific, Latin America, and Africa. Challenges to expansion would involve regulatory approvals, local healthcare system integration, reimbursement models, and competition with existing solutions.
However, no specific publicly available information or announcements about BHealthCare’s strategic plans for expansion beyond Europe and Middle East are found in the search data. For the most current, detailed insights, checking BHealthCare’s official communications or recent industry reports would be advisable.
Digital Health & AI Insights has also published articles on various topics related to the medtech industry, including "EU cybersecurity measures on medtech - what you need to know," "How data helps medtech companies adapt to market changes," and "Advancing the way to better diagnostics."
- BHealthCare's autonomous blood drawing device, HEIVA, is poised to revolutionize patient care in Europe with its innovative technology.
- By expanding in digital health, BHealthCare is leveraging technology to streamline medical-conditions diagnosis and management.
- The success of HEIVA in Europehas opened up possibilities for finance and business opportunities in the health-and-wellness sector, with potential expansion to other continents like North America, Asia-Pacific, Latin America, and Africa.
- Core aspects of BHealthCare's operations, such as their focus on science, regulatory compliance, and strategic partnerships, contribute to their competitive edge in the MedTech industry when considering growth and penetration in various global markets.
